儿童急性髓系白血病风险分层预后评分模型的开发与验证
研究利用TARGET数据库597例患儿作为训练集、本中心189例作为验证集,构建基于诊断年龄、-7/del(7q)或-5/del(5q)、核心结合因子融合基因、FLT3-ITD/NPM1状态、WT1突变及双等位基因CEBPA突变的预后模型。模型Harrell一致性指数0.68,3年和5年ROC曲线下面积分别为0.71和0.72,验证集表现优于现有预后系统,可将患者分为低、中、高危三组并识别造血干细胞移植候选者。
要点
- 模型基于诊断年龄、-7/del(7q)或-5/del(5q)、核心结合因子融合基因、FLT3-ITD/NPM1状态、WT1突变及双等位基因CEBPA突变构建。
- 训练集Harrell一致性指数0.68,3年和5年ROC曲线下面积分别为0.71和0.72。
- 模型将患者分为低、中、高危三组,预后显著不同,并成功识别造血干细胞移植候选者。
核心结论
- 新开发的预后模型在生存预测和风险分层方面表现出稳健的能力和实用性,可能有助于改进临床常规中的治疗选择。
研究设计与样本
- 从TARGET数据库下载597例患者的临床数据作为训练集,纳入本中心189例患者作为验证集。
主要发现
- 训练集中,诊断年龄、-7/del(7q)或-5/del(5q)、核心结合因子融合基因、FLT3-ITD/NPM1状态、WT1突变、双等位基因CEBPA突变与总生存期强相关并纳入模型构建。
- 预后模型表现出优异的区分能力,Harrell一致性指数为0.68,3年和5年ROC曲线下面积分别为0.71和0.72。
- 模型在验证集中得到验证,并优于现有预后系统。
- 患者被分为低、中、高危三组,预后显著不同,模型成功识别造血干细胞移植候选者。
关键数值与推荐
- 训练集597例,验证集189例。
- Harrell一致性指数0.68,3年ROC曲线下面积0.71,5年ROC曲线下面积0.72。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
To create a personal prognostic model and modify the risk stratification of paediatric acute myeloid leukaemia, we downloaded the clinical data of 597 patients from the Therapeutically Applicable Research to Generate Effective Treatments (TARGET) database as a training set and included 189 patients from our centre as a validation set. In the training set, age at diagnosis, -7/del(7q) or -5/del(5q), core binding factor fusion genes, FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD)/nucleophosmin 1 (NPM1) status, Wilms tumour 1 (WT1) mutation, biallelic CCAAT enhancer binding protein alpha (CEBPA) mutation were strongly correlated with overall survival and included to construct the model. The prognostic model demonstrated excellent discriminative ability with the Harrell's concordance index of 0.68, 3- and 5-year area under the receiver operating characteristic curve of 0.71 and 0.72 respectively. The model was validated in the validation set and outperformed existing prognostic systems. Additionally, patients were stratified into three risk groups (low, intermediate and high risk) with significantly distinct prognosis, and the model successfully identified candidates for haematopoietic stem cell transplantation. The newly developed prognostic model showed robust ability and utility in survival prediction and risk stratification, which could be helpful in modifying treatment selection in clinical routine.
引用
- Li J, Liu L, Zhang R, et al. Development and validation of a prognostic scoring model to risk stratify childhood acute myeloid leukaemia. Br J Haematol. 2022. PMID: 35880261. doi:10.1111/bjh.18354
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。